PPAR agonists as therapeutics for CNS trauma and neurological diseases - Wikidata - wikimedia - TriplyDB

PPAR agonists as therapeutics for CNS trauma and neurological diseases

PPAR agonists as therapeutics for CNS trauma and neurological diseases

http://www.wikidata.org/entity/Q37400355

about

Peroxisome proliferator-activated receptors α and γ are linked with alcohol consumption in mice and withdrawal and dependence in humans Fetal alcohol spectrum disorders and neuroimmune changes Activation of central PPAR-γ attenuates angiotensin II-induced hypertension.Role of PPAR γ in the Differentiation and Function of Neurons Activation of Sterol Regulatory Element Binding Factors by Fenofibrate and Gemfibrozil Stimulates Myelination in Zebrafish.Pathophysiology Associated with Traumatic Brain Injury: Current Treatments and Potential Novel Therapeutics.Macrophage Transcriptional Profile Identifies Lipid Catabolic Pathways That Can Be Therapeutically Targeted after Spinal Cord Injury.Glucocorticoid-Induced Leucine Zipper in Central Nervous System Health and Disease.Treatment with albumin-hydroxyoleic acid complex restores sensorimotor function in rats with spinal cord injury: Efficacy and gene expression regulation.Peroxisome proliferator-activated receptor γ (PPARγ): A master gatekeeper in CNS injury and repair.Changes in PPARδ expression in a rat model of stress-induced depression.Roles of Peroxisome Proliferator-Activated Receptor Gamma on Brain and Peripheral Inflammation.Preventive Effects of Resveratrol on Endocannabinoid System and Synaptic Protein Modifications in Rat Cerebral Cortex Challenged by Bilateral Common Carotid Artery Occlusion and Reperfusion.Regulation of brain PPARgamma2 contributes to ketogenic diet anti-seizure efficacy.Astrocyte-Specific Deletion of Peroxisome-Proliferator Activated Receptor-γ Impairs Glucose Metabolism and Estrous Cycling in Female Mice.Emerging Therapeutic Role of PPAR-α in Cognition and Emotions

P2860

Q35019725-EF8B6705-20AE-460C-9F3E-32434C43FF91 Q35294500-A86BD02A-D45F-4531-A41A-E3D3D9A1AD0F Q35841988-0732CFDD-C3F0-4E05-82CF-9F79C7A118BF Q38253356-4FAA8B73-CCF6-4679-8525-46E4A9A251E8 Q38444377-842ABC51-45E8-4C5C-824A-A12DC3ADA47B Q38887870-AFA73080-BB85-4C44-BC76-C31791A4F182 Q38994540-678AE43B-3975-48B8-9516-D0BBF27884A6 Q39021109-C4569133-11D2-43B1-8E51-2B166A2CBBB7 Q47159373-FD82B055-5BD9-46BD-9B6C-CFB59BE80178 Q47739408-212E7529-9296-426F-A7AD-5948ABFD6C6C Q47783384-5577223D-D2F0-4FDF-8A03-4C51B3FE877A Q48034616-5F68CDE3-FE27-4507-984E-640C045746CF Q48133937-011B7602-965F-46F2-B5CB-E121BF62C7D5 Q48569089-0EAB5EA7-9E9A-429B-9E5E-F917A2569BFD Q53087310-B31D0B53-38E7-407A-BE86-45A061131997 Q57818280-F5C32682-8D58-400E-97DC-325373368ED9

P2860

PPAR agonists as therapeutics for CNS trauma and neurological diseases

http://www.wikidata.org/entity/Q37400355

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 18 December 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

PPAR agonists as therapeutics for CNS trauma and neurological diseases

@en

PPAR agonists as therapeutics for CNS trauma and neurological diseases.

@nl

type

label

PPAR agonists as therapeutics for CNS trauma and neurological diseases

@en

PPAR agonists as therapeutics for CNS trauma and neurological diseases.

@nl

prefLabel

PPAR agonists as therapeutics for CNS trauma and neurological diseases

@en

PPAR agonists as therapeutics for CNS trauma and neurological diseases.

@nl

P1433

Q37400355-5ED5C7CA-A23F-4B70-A074-C30A41F54E39

P1476

Q37400355-B59FB6A2-A811-4047-848A-2657BB88268D

P2093

Q37400355-12817A28-B166-4A62-A791-042FE2292E2B

Q37400355-1BCE0484-014B-486D-8582-A6D89D0B9664

Q37400355-24D9A67C-EBD7-45B6-B542-65BCA3EE5D08

Q37400355-AD4FAECD-F246-4E56-A0DE-29992B7755AA

P275

Q37400355-323F020B-63BF-48B4-9E15-5C88451AB836

P2860

Q37400355-00D8BEA2-7710-4E13-A1A7-68B730DED109

Q37400355-0137C5A6-15C8-4EFE-9842-13D4967C2279

Q37400355-056CDA11-D81E-4941-B12A-27484D770745

Q37400355-06B5C6FD-DEA6-46F9-AC78-BFB6FDC00C18

Q37400355-07D374EA-1EB3-4558-B07B-C4105127DF8E

Q37400355-08063A09-C002-4511-9256-336FD639BAF0

Q37400355-08247627-E55F-4DB1-BBF8-2C72422842E9

Q37400355-096F71F3-2A8C-492D-933D-7981DB459933

Q37400355-099E02AB-40ED-43A4-9913-51F6A45291BA

Q37400355-0C2E9E07-A2C8-4D56-8FF0-E08F545006AC

P304

Q37400355-BFC62A85-B8A9-4451-965E-119A7906E016

P31

Q37400355-26ECB563-0F8B-4714-BE4E-ABF188028F1F

Q37400355-F766470A-8845-4F09-9AE2-034AE9D5B800

P356

Q37400355-81DBDBFE-0713-4585-8E90-518DF14272DE

P433

Q37400355-48D26D97-A729-437E-8166-870380889F18

P478

Q37400355-88B24EDB-2924-4938-B440-782028B219A6

P5008

Q37400355-D1D7B130-DE11-444F-894F-D5127CB0DC5B

P577

Q37400355-6FC4B9E9-163C-4475-8D60-984386253DBA

P698

Q37400355-4AA02D05-2C4A-47D8-A153-55F9132B1788

P921

Q37400355-3419C5E4-C010-4D7F-A894-D30C83EB04F2

Q37400355-79AF4B91-3A93-463C-BAD3-37FCA4E53CEF

Q37400355-F02DEFFF-04BF-43E4-A835-B500841B7D07

P932

Q37400355-24C85E56-CF8E-4875-B536-E4CF3050E769

P356

P1433

P1476

PPAR agonists as therapeutics for CNS trauma and neurological diseases

@en

P2093

Andrew Sauerbeck

http://www.w3.org/2001/XMLSchema#string

Dana M McTigue

http://www.w3.org/2001/XMLSchema#string

Phillip G Popovich

http://www.w3.org/2001/XMLSchema#string

Shweta Mandrekar-Colucci

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 3.0 Unported

P2860

ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models

Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study

Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes

PPAR-delta senses and orchestrates clearance of apoptotic cells to promote tolerance

Exploring the full spectrum of macrophage activation

MitoNEET is a uniquely folded 2Fe 2S outer mitochondrial membrane protein stabilized by pioglitazone

Rho activation patterns after spinal cord injury and the role of activated Rho in apoptosis in the central nervous system

Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo

Astrocytes initiate inflammation in the injured mouse spinal cord by promoting the entry of neutrophils and inflammatory monocytes in an IL-1 receptor/MyD88-dependent fashion.

Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe

P304

e00129

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1042/AN20130030

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2013-12-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24215544

http://www.w3.org/2001/XMLSchema#string

P921

intracellular receptor

neurological disorder

transcription factor

P932

3866683

http://www.w3.org/2001/XMLSchema#string